A commercial airliner flies Northwest across Lake Michigan in front of the "Full Buck" supermoon, the first of four supermoons in 2023, July 3, 2023, in Chicago. The cosmos is offering up a double feature in August: a pair of supermoons. Catch the first show Tuesday night, Aug. 2, as the full moon rises in the southeast. (AP Photo/Charles Rex Arbogast, File)
The cosmos is offering up a double feature in August: a pair of supermoons culminating in a rare blue moon.
Catch the first show Tuesday evening as the full moon rises in the southeast, appearing slightly brighter and bigger than normal. That’s because it will be closer than usual, just 222,159 miles (357,530 kilometers) away, thus the supermoon label.
The moon will be even closer the night of Aug. 30 — a scant 222,043 miles (357,344 kilometers) distant. Because it’s the second full moon in the same month, it will be what's called a blue moon.
“Warm summer nights are the ideal time to watch the full moon rise in the eastern sky within minutes of sunset. And it happens twice in August,” said retired NASA astrophysicist Fred Espenak, dubbed Mr. Eclipse for his eclipse-chasing expertise.
The last time two full supermoons graced the sky in the same month was in 2018. It won’t happen again until 2037, according to Italian astronomer Gianluca Masi, founder of the Virtual Telescope Project.
Masi will provide a live webcast of Tuesday evening’s supermoon, as it rises over the Coliseum in Rome.
“My plans are to capture the beauty of this ... hopefully bringing the emotion of the show to our viewers,” Masi said in an email.
“The supermoon offers us a great opportunity to look up and discover the sky,” he added.
This year’s first supermoon was in July. The fourth and last will be in September. The two in August will be closer than either of those.
Provided clear skies, binoculars or backyard telescopes can enhance the experience, Espenak said, revealing such features as lunar maria — the dark plains formed by ancient volcanic lava flows — and rays emanating from lunar craters.
According to the Old Farmer’s Almanac, the August full moon is traditionally known as the sturgeon moon. That’s because of the abundance of that fish in the Great Lakes in August, hundreds of years ago.
Healthcare workforce management platform ShiftMed
recently announced a $45 million funding round.
The company's platform connects nurses and healthcare professionals to hospitals and other healthcare providers.
ShiftMed's new funding comes amid widespread labor shortages in the healthcare sector. The company's CEO Todd Walrath joins Cheddar News' Closing Bell to discuss.
Universities like UCLA, Yale, and Duke have announced they're implementing remote learning amid the COVID omicron variant surge, despite President Biden recommending that K-12 schools should continue in-person education. Jared C. Bass, senior director for Higher Education at American Progress, joined Cheddar to break down what institutions of higher education might be considering differently. "I think some universities are allowing periods of a bit of a respite to allow students to get testing and make sure when they do return back to campus that they're healthy," he noted.
Supply chain issues have become one of the biggest roadblocks for the U.S. EV market, with production woes likely to stunt the industry's growth in 2022. Rich Steinberg, electric vehicle expert and industry advisor, told Cheddar that the Biden administration investing in domestic mining for essential minerals used in battery manufacturing — such as lithium — could help alleviate the bottlenecks. "Some of those same materials are available domestically, they just haven't been prioritized," he said, noting the paradox between green tech and "dirty" mining. "The good news is that there are ways to extract those materials cleanly."
Hyperfine, the pioneer of the very first FDA-approved portable MRI device, made its public debut on the Nasdaq via a SPAC merger. CEO Dave Scott joined Cheddar's "Opening Bell" to discuss the IPO launch, the company's valuation at $580 million, and the impact of its machine called Swoop. "We can roll an MRI system, our MRI Swoop system, right into the room where you are, right up to your patient bedside, and scan you right there and get an image in less than an hour," he explained.
Dr. Rob Davidson, Executive Director of the Committee to Protect Health Care and an ER Physician in West Michigan, joins Cheddar News to break down the expectations of Pfizer's new COVID-19 treatment pill.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
